5-HT receptors mediating contractions of the isolated human coronary artery.
We investigated contractile responses of the isolated human coronary artery to 5-hydroxytryptamine (5-HT), washed human platelets, sumatriptan and ergotamine. 5-HT (pD2: 6.8 +/- 0.1, Emax: 47.7 +/- 6.8 mN) and platelets (effect 14.4 +/- 2.8 mN with 3.10(10) platelets/l) caused contractile responses which were attenuated by ketanserin (1 microM). In the presence of ketanserin (1 microM), both rauwolscine (1 and 10 microM) and cyanopindolol (1 and 10 microM) caused concentration-dependent additional antagonism against contractions induced by low (< or = 1 microM) concentrations of 5-HT. Sumatriptan-induced contractions (pD2: 6.2 +/- 0.1; Emax: 10.7 +/- 2.4 mN) were antagonized to a similar extent by both rauwolscine (1 microM) and cyanopindolol (1 microM) (pKB: 6.5 +/- 0.1 and 6.4 +/- 0.1, respectively) and also by metergoline (0.1 microM; pKB: 7.2 +/- 0.1). The order of potency of antagonists against sumatriptan resembles the order reported for the human saphenous vein 5-HT1D-like receptor. No significant additional antagonism by cyanopindolol (1 microM) or rauwolscine (1 microM) against platelet-induced contractile responses was observed. Ergotamine caused potent contractile responses (pD2: 8.4 +/- 0.3, Emax: 19.4 +/- 2.4 mN). It is concluded that although 5-HT2 receptors predominantly mediate 5-HT-induced contractions, the 5-HT1-like receptor seems to play a role in coronary vasospasm caused by low concentrations of 5-HT.
Bax
W A
WA
Department of Pharmacology, Erasmus University Rotterdam, Netherlands.
Renzenbrink
G J
GJ
Van Heuven-Nolsen
D
D
Thijssen
E J
EJ
Bos
E
E
Saxena
P R
PR
D000293:Adolescent; D000328:Adult; D001158:Arteries / Q000187:drug effects / Q000502:physiology; D001792:Blood Platelets / Q000502:physiology; D002648:Child; D002675:Child, Preschool; D003331:Coronary Vessels / Q000187:drug effects / Q000502:physiology*; D004305:Dose-Response Relationship, Drug; D004878:Ergotamine / Q000494:pharmacology*; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D007223:Infant; D007650:Ketanserin / Q000494:pharmacology; D008297:Male; D008711:Metergoline / Q000494:pharmacology; D008875:Middle Aged; D009119:Muscle Contraction / Q000187:drug effects; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000502:physiology*; D010869:Pindolol / Q000031:analogs & derivatives / Q000494:pharmacology; D011188:Potassium / Q000494:pharmacology; D011985:Receptors, Serotonin / Q000502:physiology*; D012701:Serotonin / Q000494:pharmacology; D012702:Serotonin Antagonists; D013373:Substance P / Q000494:pharmacology; D018170:Sumatriptan / Q000494:pharmacology*; D015016:Yohimbine / Q000494:pharmacology
D011985:Receptors, Serotonin; D012702:Serotonin Antagonists; D008711:Metergoline; D015016:Yohimbine; D012701:Serotonin; D013373:Substance P; C047975:cyanopindolol; D018170:Sumatriptan; D007650:Ketanserin; D010869:Pindolol; D004878:Ergotamine; D011188:Potassium